NEW YORK, August 1, 2026 (Newswire.com) - Quick disclosure before you dive in: this is a paid advertorial, and a commission may be earned if you enroll through a link here
: While Saxenda offers less weight loss than some newer agents, a generic option may expand treatment to broader patient populations and open the door for additional offpatent GLP1s
The US Food and Drug Administration (FDA) has approved an additional indication for the weight loss drug semaglutidemarketed as Wegovy (Novo Nordisk) to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight along with a reduced calorie diet and increased physical activity
Getting adequate, good-quality sleep is important for appetite regulation and supporting energy levels
However, the combination isnt without risks, particularly for individuals who are prone to low blood sugar
How can I start using oral tirzepatide